A research team led by scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has determined how several antibodies induced by Epstein-Barr virus (EBV), a herpesvirus that causes infectious mononucleosis and is associated with certain cancers, block infection of cells grown in the laboratory.

This transmission electron microscopic (TEM) image revealed the presence of numerous Epstein-Barr virus (EBV) virions/CDC
This transmission electron microscopic (TEM) image revealed the presence of numerous Epstein-Barr virus (EBV) virions/CDC

They then used this information to develop novel vaccine candidates that, in animals, elicited potent anti-EBV antibody responses that blocked infection of cell types involved in EBV-associated cancers.

Currently, there is no licensed vaccine for EBV. The virus is associated with certain cancers (nasopharyngeal and gastric) of epithelial cells, which form the lining of the body’s surfaces, as well as Burkitt and Hodgkin lymphomas, which are cancers of the immune system’s B cells. Worldwide, about 200,000 cases of EBV-associated cancers occur annually, resulting in 140,000 deaths.

Jeffrey I. Cohen, M.D., and Wei Bu, Ph.D., both of NIAID, led the investigation. Prior efforts to develop an EBV vaccine focused on a viral surface protein, gp350, that the virus uses to enter B cells. However, EBV infects not only B cells, but also epithelial cells that line the mouth and upper throat. These cells are usually infected after contact with saliva from an EBV-infected individual.

Read more at NIH

Epstein-Barr Virus: The red-headed step child of the Herpes Virus family

Experimental universal influenza vaccine candidate, H1ssF_3928, in human trials

Oral norovirus vaccine to enter Phase 1b trial

Dengue vaccine passes FDA Advisory Committee hurdle

Vaccines: Large study demonstrates no link found between MMR vaccine and autism